SignatureChipOS™
Approximately 105,000 oligonucleotide probes provide whole genome coverage, including over 150 microdeletion and duplication syndromes, the pericentromeric, and subtelomeric regions. The SignatureChipOS™ is designed with an average of 50 oligonucleotides per clinical locus (a five-fold increase over any other clinical oligo microarray).
Indications for Use
Signature Genomics suggests the SignatureChipOS™ in pregnancies with:
- Abnormal karyotype requiring further characterization
- Abnormal karyotypes that are de novo and apparently balanced
- Suspicion for an imbalance in a specific gene region that is best evaluated by microarray
- Prenatal sample from pregnancy with abnormalities that has either delivered or miscarried
The decision to evaluate at this level must be balanced against the possibility of finding results of unclear clinical relevance. This decision is made on a case-by-case basis based on the indication for study provided on the requisition form and/or documented discussion of the case between our genetic counselors or Directors with the patient's health care provider. Due to the extensive coverage and high resolution of this microarray, there is a higher possibility of obtaining results with unclear clinical significance than with other microarray tests offered by Signature Genomics.
Technical Specifications
- Oligonucleotide-based microarray
- ~105,000 oligonucleotide probes
- >200 Clinically recognized syndromes
- On average, 50 probes per clinical locus
- Probes every 10 kb in regions of clinical interest
- Probes every 35 kb provide whole-genome backbone coverage